[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:ccnd1-gene":3},{"name":4,"total":5,"recruiting":5,"trials":6},"CCND1 Gene",8,[7,15,22,29,35,41,47,53],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05976763","Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma",[11],"Phase 3","RECRUITING","2026-08-26T02:17:07.954622Z","2026-07-19T19:36:05.124289Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT03310879","Study of the CDK4\u002F6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6",[19],"Phase 2","2026-08-26T02:17:39.048487Z","2026-05-05T02:43:29.160779Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT05861050","Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma",[26],"Phase 1\u002FPhase 2","2026-08-26T02:19:25.538428Z","2026-05-05T02:43:28.958425Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":33,"content_modified":34},"NCT06357676","Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial",[26],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:28.817702Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT02523014","Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas",[19],"2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.482521Z",{"nct_id":42,"title":43,"phases":44,"status":12,"updated_at":45,"content_modified":46},"NCT02896335","Palbociclib and Pembrolizumab In Central Nervous System Metastases",[19],"2026-08-26T02:18:38.865010Z","2026-07-24T01:27:14.926741Z",{"nct_id":48,"title":49,"phases":50,"status":12,"updated_at":51,"content_modified":52},"NCT05843253","Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant",[19],"2026-08-26T02:19:31.671303Z","2026-05-05T02:43:29.388169Z",{"nct_id":54,"title":55,"phases":56,"status":12,"updated_at":57,"content_modified":58},"NCT04040205","Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration",[19],"2026-08-26T02:18:07.037408Z","2026-05-05T02:43:28.417090Z"]